PRESS RELEASES

Date Title View
Toggle Summary Chimerix to Present at Credit Suisse 29th Annual Healthcare Conference
DURHAM, N.C. , Nov. 05, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that Mike Sherman , Chief Executive Officer, will present a corporate overview and
View HTML
Toggle Summary Chimerix Reports Third Quarter 2020 Financial Results and Provides Operational Update
– C ompleted R olling NDA S ubmissions for Both BCV Tablet and S uspension   Formulations as M edical C ountermeasure for S mallpox   – – F irst Patient Visit for DSTAT Phase 3 AML Study Expected in Early 2021 – – C ompany Well Capitalized Through Several Expected Upcoming Milestones – – C
View HTML
Toggle Summary Chimerix to Report Third Quarter 2020 Financial Results and Provide an Operational Update on November 5, 2020
DURHAM, N.C. , Oct. 29, 2020 (GLOBE NEWSWIRE) -- Chimerix  (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that it will host a live conference call and audio webcast on Thursday, November 5,
View HTML
Toggle Summary Chimerix to Participate in Upcoming Investor Conferences
DURHAM, N.C. , Sept. 10, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that management will participate in the following investor conferences in September:
View HTML
Toggle Summary Chimerix Reports Second Quarter 2020 Financial Results and Provides Operational Update
– Completion of BCV NDA Rolling Submission Planned for Third Quarter 2020 – –  Currently Enrolling Phase 2/3 Study of DSTAT in Patients with COVID-19;  Phase 2 Enrollment Completion Expected in Fourth Quarter – – Startup Activities for DSTAT Phase 3 AML Study Initiated;    Site Activation Expected
View HTML
Toggle Summary Chimerix to Report Second Quarter 2020 Financial Results and Provide an Operational Update on August 10, 2020
DURHAM, N.C. , Aug. 03, 2020 (GLOBE NEWSWIRE) -- Chimerix  (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that it will host a live conference call and audio webcast on Monday, August 10,
View HTML
Toggle Summary Chimerix Appoints Allen Melemed, M.D. as Chief Medical Officer
Former Eli Lilly Veteran Brings Deep Oncology Clinical and Regulatory Expertise DURHAM, N.C. , June 22, 2020 (GLOBE NEWSWIRE) -- Chimerix  (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced the
View HTML
Toggle Summary Chimerix to Present at H.C. Wainwright Virtual Fireside Chat Series
DURHAM, N.C. , June 18, 2020 (GLOBE NEWSWIRE) -- Chimerix  (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that Company management, including Mike Sherman , Chief Executive Officer, and Mike
View HTML
Toggle Summary Chimerix to Present at Jefferies Virtual Healthcare Conference
DURHAM, N.C. , May 28, 2020 (GLOBE NEWSWIRE) -- Chimerix  (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that Mike Sherman , Chief Executive Officer, will present a corporate overview and
View HTML
Toggle Summary Chimerix Reports First Quarter 2020 Financial Results and Provides Operational Update
DSTAT Explored as a Potential Novel Treatment for the Current Pandemic While an NDA is Being Prepared for Brincidofovir to Address a Potential Future Pandemic  DURHAM, N.C. , May 07, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development
View HTML